Clinical trials: Glioblastoma (GBM), open to volunteers
Malignant Glioma of Brain, Astrocytoma
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent…
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor
- Trial name
- NCT05686798
- Testing
- Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Glioblastoma (GBM)
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
A Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
- Trial name
- NCT07244666
- Testing
- Metabolically Armed EGFRvIII CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Glioblastoma (GBM)
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
The goal of this clinical trial is to learn if a combined treatment approach can treat glioblastoma (GBM) with ventricular invasion or meningeal metastasis in adults.
- Trial name
- NCT07193654
- Testing
- Intrathecal injection of thiotepa, Stupp regimen (oral temozolomide), Radical radiotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Glioblastoma (GBM)
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
Glioblastoma (GBM) is an aggressive malignancy of the central nervous system. Older adults with GBM have a unique constellation of medical, psychosocial, and supportive care needs.
- Trial name
- ELITE-GBM (NCT06835803)
- Testing
- Dose-escalated radiation therapy, Standard hypofractionated radiation
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Brigham and Women's Hospital
GBM, Glioblastoma Multiforme (GBM)
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
The goal of this clinical trial is to evaluate the safety and feasibility of focused ultrasound (FUS)-mediated blood-brain barrier (BBB) disruption using the Next Generation Dome Helmet (NGDH) in adults with glioblastoma (GBM)…
- Conditions
- GBM, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme of Brain, Glioblastoma Multiforme Glioma
- Trial name
- NCT07179328
- Testing
- Focused Ultrasound Next Generation Dome Helmet, Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Sunnybrook Health Sciences Centre
Glioblastoma (GBM), Glioblastoma Multiforme (GBM)
Allogeneic γδT Cells in Glioblastoma
This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic γδ T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT γδT cells) in patients with…
- Trial name
- ABOUT (NCT07144735)
- Testing
- Allogeneic γδ T (ABOUT) cells
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Peking University Third Hospital
Glioblastoma (GBM)
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
This Phase II trial tests if sonodynamic therapy (SDT)-a non-invasive treatment using ultrasound to activate a cancer-killing drug-improves outcomes for newly diagnosed glioblastoma patients.
- Trial name
- NCT07130149
- Testing
- Sonodynamic Therapy (SDT), Standard Treatment
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Yingjuan Zheng
Glioma, Glioma Tumor Recurrence
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
The purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmacokinetic characteristics of BC008-1A injection in subjects with recurrent CNS WHO grade 4 glioma.
- Conditions
- Glioma, Glioma Tumor Recurrence, Glioma, Recurrent High Grade, Glioblastomas (GBM)
- Trial name
- NCT06773481
- Testing
- BC008-1A
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Glioblastoma (GBM), Diffuse Midline Glioma (DMG)
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
- Conditions
- Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Trial name
- NCT06896110
- Testing
- Nivolumab, Azacitidine (AZA), lumbar puncture
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Andrew P. Groves
Glioblastoma, IDH-wildtype, Glioblastoma
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of…
- Conditions
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Trial name
- NCT05879367
- Testing
- Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1)
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Orbus Therapeutics, Inc.
Glioblastoma Multiforme (GBM)
Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected.
- Trial name
- NCT06939400
- Testing
- Photodynamic therapy (PDT), GBM patients recevied traditional treatment options
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Provincial People's Hospital
Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
This phase I/II clinical trial evaluates the safety, efficacy, and prognostic potential of [18F]AlF-NOTA-PCP2 PET/CT imaging in assessing PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell…
- Conditions
- Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
- Trial name
- PD-L1-PET (NCT06690216)
- Testing
- PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Man Hu
Glioblastoma, Glioblastoma Multiforme (GBM)
Patient's Derived Organoids for Drug Screening in Glioblastoma
The study will enroll patients suffering from glioblastoma, a malignant brain tumor. Intervention is intended as a laboratory intervention and not as a clinical intervention.
- Conditions
- Glioblastoma, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme, Adult
- Trial name
- GlioPDO (NCT06781372)
- Testing
- Development and characterization of PDOs, Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Glioblastoma, Glioblastoma WHO Grade IV
CSF Proteomic Characterization of Glioblastomas
The goal of this observational study is to identify proteins that can be found in the cerebrospinal fluid (CSF) of patients with grade IV brain tumors, specifically glioblastomas, and correlate these proteins with progression…
- Conditions
- Glioblastoma, Glioblastoma WHO Grade IV, Glioblastoma (GBM), Glioblastoma Multiforme of the Brain
- Trial name
- NCT06845020
- Volunteers
- 15 people
- Sponsor
- Univeridad Autonoma de Guadalajara
Glioblastoma (GBM)
Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases
This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.
- Trial name
- AiD-GLIO (NCT05911230)
- Testing
- Advanced diffusion-weighted MRI (ADW-MRI)
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- University Hospital, Basel, Switzerland
Glioblastoma (GBM)
Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients
The goal of this clinical trial is to learn if NRG103 works to treat recurrent GBM in adults. It will also learn about the safety of NRG103.
- Trial name
- NCT06757153
- Testing
- NRG-103
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhongnan Hospital
Recurrent Glioblastoma Multiforme (GBM)
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM
- Trial name
- NCT06616727
- Testing
- SNC109
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
Glioblastoma Multiforme (GBM)
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
This study was designed to evaluate the safety, tolerability, efficacy and pharmacokinetics of JK-1201I combined with adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and concomitant…
- Trial name
- NCT06595186
- Testing
- JK-1201I, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- JenKem Technology Co., Ltd.
GBM
Integrative Analysis of Human Glioblastoma Multiforme
Integrative analysis of GBM
- Trial name
- NCT03005132
- Testing
- Normal brain tissue
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Shanghai 10th People's Hospital